...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Debt

For those wondering how the lights stay on, as of Jan. 31/22 there was a $1.5 million loan from Newsoara and almost $1.9 million of Promissory Notes out. The Newsoara loan was taken March/21 and subsequent to Jan.31/22 the maturity date was amended to June 30/22. Details on the Promissory Notes are copied below. $1 million of it is at 11%.

Promissory notes (continued)

As at January 31, 2022, promissory notes totaling $1.9 million are due to three related party lenders. During the nine months ended January 31, 2022:

• the Chief Executive Officer / Chairman of the Company lent an additional CAD$0.5 million and was repaid CAD$0.4 million (the outstanding $0.6 million (CAD$0.8 million) promissory note bears interest at 5%, is payable on demand and is secured);

• another director of the Company lent an additional CAD$0.1 million to the Company and was repaid CAD $0.1 million (the outstanding $0.2 million (CAD$0.3 million) promissory note bears interest at 5% per annum, is unsecured and is payable on demand);

• a relative of the Chief Executive Officer / Chairman of the Company lent an additional $0.7 million and was repaid $0.3 million (the outstanding $1.0 million promissory note bears interest at 11% per annum, is payable on demand and is secured);

• the Chief Financial Officer lent CAD$20 thousand and was repaid CAD$20 thousand (the promissory note bore interest at 8% per annum while it was outstanding); and

• a third party lent $63 thousand and was repaid $63 thousand (the promissory note bore interest at 8% per annum while it was outstanding).

 In connection with the $0.7 million total promissory note advanced by a relative of the Chief Executive Officer / Chairman of the Company ($0.3 million was advanced in October 2021 and $0.4 million was advanced in January 2022), the Company issued a total of 350,000 warrants. Each warrant is exercisable at a price of $0.75 per underlying common share for a period of five years from the respective grant dates. The combined fair value of the 350,000 warrant

4
Apr 03, 2022 09:50AM
4
Apr 03, 2022 12:26PM
2
Apr 03, 2022 01:04PM
3
Apr 03, 2022 03:47PM
4
Apr 03, 2022 04:08PM
1
Apr 03, 2022 04:30PM
6
Apr 03, 2022 04:55PM
2
Apr 04, 2022 09:48AM
5
Apr 04, 2022 10:29AM
2
Apr 04, 2022 10:39AM
4
Apr 04, 2022 03:10PM
7
Apr 05, 2022 08:47PM
4
Apr 06, 2022 07:43AM
2
Apr 06, 2022 09:55AM
2
Apr 06, 2022 10:29AM
2
Apr 06, 2022 10:35AM
3
Apr 06, 2022 11:38AM
1
Apr 07, 2022 12:40PM
Share
New Message
Please login to post a reply